CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome

Trial Title: CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome

NCT ID: NCT05963191

Condition: Lynch Syndrome

Conditions: Official terms:
Colorectal Neoplasms, Hereditary Nonpolyposis
Syndrome

Conditions: Keywords:
Lynch Syndrome
CAD EYE
adenoma detection rate
colorectal screening
artificial intelligence

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Diagnostic

Masking: Single (Participant)

Intervention:

Intervention type: Device
Intervention name: Colorectal cancer screening with CAD EYE colonoscopy
Description: The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa. In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis.
Arm group label: CAD-EYE group: Colorectal cancer screening with CAD EYE colonoscopy

Summary: Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one of the DNA mismatch repair genes (path_MMR) MLH1, MSH2, MSH6, PMS2 or a deletion in the 3' region of the Epcam gene. Patients followed up for LS are at high risk of developing CRC at an early age, and have a high cumulative CRC risk. In this context, CRC screening by colonoscopy is of major importance, as it is associated with a reduction in both CRC incidence and mortality. In France, the Institut National du Cancer (INCa) recommends colonoscopy with indigo carmine chromoendoscopy (CE), as it is associated with a significant increase in the adenoma detection rate (ADR) compared with white light. However, EC is not routinely performed in clinical practice, as it is a time-consuming technique requiring a dedicated slot with a trained operator. Recent years have seen the emergence of artificial intelligence techniques for real-time polyp detection aids or CADe devices. These easy-to-use systems have shown very promising results compared with high-definition (HD) white light. Indeed, data from the first meta-analysis of 5 randomized controlled trials (4354 patients) confirmed a significantly higher ADD in the CADe group than in the HD group (36.6% vs. 25.2%; 95% CI], 1.27-1.62; P < 0.01; I2 Z 42%) 10. The CAD EYE system (Fujifilm) is a CADe device supporting both detection (sensitivity > 95%) and characterization of colonic polyps in real time. To date, artificial intelligence has never been evaluated for CRC screening in patients followed up for LS. The aim of this work is to evaluate the effectiveness of the CAD EYE system in this specific population. To this end, we intend to conduct a randomized, controlled, non-inferiority trial comparing CAD EYE with CE in patients with LS.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Confirmed pathogenic mutation (path_MLH1, path_MSH2, path_MSH6, path_PMS2, path_EpCAM) - Male or female of legal age at time of colonoscopy prescription. - Patient agreeing to participate in the study - Person affiliated with or benefiting from a social security scheme - Free, informed and express consent Exclusion Criteria: - Patient undergoing total colectomy with ileoanal or ileosigmoid anastomosis - Patient with a history of Crohn's disease or ulcerative colitis - Patients with a known allergy or intolerance to polyethylene glycol and ascorbic acid. - Patients unable to undergo fractionated colonic preparation - Inadequate colonic preparation: Boston sub-score <2 per segment - Patient under guardianship or protected person - Patient who does not understand French or cannot read - Person not affiliated to a Social Security system. - Pregnant women

Gender: All

Minimum age: 18 Years

Maximum age: 90 Years

Healthy volunteers: No

Start date: October 2, 2023

Completion date: October 2, 2025

Lead sponsor:
Agency: PERROD Guillaume
Agency class: Other

Source: French Society of Digestive Endoscopy

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05963191